Veterinary Artificial Insemination Global Market Report 2025

The veterinary artificial insemination market size has grown strongly in recent years. It will grow from $4.29 billion in 2024 to $4.56 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to genetic improvement programs, increased productivity and efficiency, improved animal health and disease control, cost-effectiveness and access to superior genetics.

The veterinary artificial insemination market size is expected to see strong growth in the next few years. It will grow to $6.11 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to education and training, genetic enhancement programs, health and disease control, sustainable agriculture and environmental concerns, global demand for animal protein. Major trends in the forecast period include precision breeding, focus on livestock productivity and efficiency, health and disease management, sustainable agriculture practices, expansion into new markets and species.

The forecast of 7.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariffs on semen storage and insemination equipment could raise procedure costs and limit access to quality reproduction services in the veterinary field. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing demand for animal protein is anticipated to drive the growth of the veterinary artificial insemination market in the future. Animal protein is a protein source derived from animals, providing a complete amino acid profile for the body. This benefit has led to a heightened need for veterinary artificial insemination to produce more animals in a shorter timeframe. For example, in February 2024, GOV.UK, the UK government's official website, reported that in 2022, the value of beef and veal increased by 12% to £3.8 billion, with home-fed production rising by 2% to 928 thousand metric tons. Additionally, the value of pig meat surged by 18% to £1.7 billion, while home-fed production grew by 0.5% to 1.0 million metric tons. Consequently, the demand for animal protein is fueling the growth of the veterinary artificial insemination market.

The growing demand for livestock is another factor expected to drive the expansion of the veterinary artificial insemination market. Livestock, comprising domesticated animals raised for various agricultural purposes, such as meat, milk, eggs, wool, and leather, are pivotal in meeting the global demand for animal-derived products. Veterinary artificial insemination (AI) is a widely employed technique in livestock production to enhance breeding by introducing semen into the female reproductive tract without natural mating. This approach not only improves the quality of livestock but also enhances productivity. According to the United States Department of Agriculture, in October 2023, the European Union (EU) is projected to account for 15% of global pork, beef, and chicken meat exports by 2024. Additionally, global beef and veal production increased from 58,361 in 2021 to 59,285 in 2022. The escalating demand for livestock contributes significantly to the growth of the veterinary artificial insemination market.

Major companies and governments involved in the veterinary artificial insemination market are concentrating on developing innovative products, including livestock care services, to deliver reliable services to customers. Livestock care services include a comprehensive range of professional practices aimed at enhancing the health, well-being, and productivity of farm animals. These services play a crucial role in sustaining profitable livestock production, ensuring the safety of animal products, and protecting public health. For example, in April 2023, the Government of Himachal Pradesh, an authority in India, initiated Project Sanjeevani. This project is specifically designed to provide doorstep veterinary services, especially in remote areas. It addresses the difficulties faced by livestock owners in obtaining timely and quality veterinary care. By utilizing teleconsultation and mobile applications, veterinary professionals can engage with farmers in distant locations, offer real-time advice, and facilitate timely interventions. The doorstep veterinary services are expected to encompass curative treatments, vaccinations, artificial insemination, preventive care, and comprehensive animal husbandry-related information.

Veterinary artificial insemination (AI) involves the manual introduction of fresh male animal sperm or a thawed frozen sperm suspension into the female animal's reproductive organs. This procedure addresses logistical challenges associated with natural copulation. It finds application in selective breeding, genetic enhancement, resolving infertility issues, and conservation across various animal species, including cattle, companion animals, and wildlife.

The primary products within veterinary artificial insemination include normal semen and sexed semen. Normal semen is utilized for artificial insemination to improve the genetics and reproduction of farm animals. On average, a typical ejaculation yields 1.5 to 5 milliliters of semen, containing sperm ranging from 15 million to over 200 million per milliliter. This technique is applied in cattle, swine, ovine and caprine, equine, and other species, employing methods such as intracervical insemination, intrauterine insemination, intrauterine tub peritoneal insemination, and intratubal insemination. Veterinary hospitals, veterinary clinics, and related facilities typically carry out these procedures.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a considerable impact on the veterinary healthcare sector, particularly in the supply of pharmaceuticals, medical devices, and animal care products. Increased duties on imported veterinary medicines, diagnostic equipment, surgical tools, and pet care supplies have driven up operational costs for veterinary clinics, animal hospitals, and livestock health providers, forcing them to either raise service charges or absorb reduced profit margins. The livestock and agricultural industries are facing similar pressures, as tariffs on feed additives, vaccines, and breeding equipment push up production costs and complicate animal health management. Furthermore, retaliatory tariffs in major export markets have weakened demand for U.S.-manufactured veterinary products, adding to revenue challenges. To navigate these headwinds, the sector must now focus on local sourcing, preventive healthcare strategies, and digital veterinary solutions to control costs while continuing to deliver quality animal care.

The veterinary artificial insemination market research report is one of a series of new reports that provides veterinary artificial insemination market statistics, including veterinary artificial insemination industry global market size, regional shares, competitors with a veterinary artificial insemination market share, detailed veterinary artificial insemination market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary artificial insemination industry. This veterinary artificial insemination market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leading companies in the veterinary artificial insemination market are focused on creating innovative products, such as fertile sexed semen, to achieve a competitive advantage. Fertile sexed semen refers to semen that contains sperm capable of fertilizing an egg, potentially resulting in pregnancy. This type of semen is utilized in artificial insemination (AI), a procedure that involves inserting sperm into the uterus to achieve pregnancy. For instance, in September 2022, Cogent Breeding Ltd., a UK-based provider of sexed semen technology and modern dairy farming tools, introduced Ultraplus. This is the next generation of gender-sorted semen, offering a significant enhancement in conception rates, making it the highest fertility gender-sorted semen available to date. Ultraplus is now part of 90% of Cogent's dairy offerings, and an increasing number of beef sires are also being offered in Ultraplus male sexed form. The Ultraplus range provides 96-97% gender accuracy, depending on the requirement for female dairy calves or male beef calves.

Major companies in the veterinary artificial insemination sector are concentrating on establishing specialized laboratories to better meet market demands. A specialized laboratory is a facility that is specifically designed and staffed to carry out certain types of scientific research, testing, or analysis. For example, in November 2022, the National Cattle Breeding Centre (NCBC), an Ireland-based cattle breeding organization, launched a sexed semen lab in Naas, Co. Kildare. This lab will enhance the availability of sexed straws for customers of Progressive Genetics and Munster Bovine during the breeding season.

Major companies operating in the veterinary artificial insemination market are Swine Genetics International, Semex, Gènes Diffusion, CRV Holding B.V., Select Sires Inc., Shipley Swine Genetics, STgenetics, Hamilton Thorne Inc., Microptic, Medical Electronic Systems LLC., Magapor S.L., Proiser, Zoetis India Limited, GenePro Inc., IMV Technologies, Neogen Corporation, Bovine Elite LLC., Agtech Inc., Genex Cooperative Inc., Alta Genetics Inc., ABS Global Inc., Cogent Breeding Ltd., Viking Genetics, Inseme S.r.l., Semen Cardona S.L., Genus PLC, Trans Ova Genetics, Cattle Genetics Ltd., Cattle Breeding Services.

North America was the largest region in the veterinary artificial insemination market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary artificial insemination market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the veterinary artificial insemination market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The veterinary artificial insemination market consists of revenues earned by entities by providing veterinary artificial insemination services such breeding, scientific doorstep AI facilities, crossbreeding, selective breeding, pure breeding. The market value includes the value of related goods sold by the service provider or included within the service offering. The veterinary artificial insemination market also includes sales of AI kit, AI gun, AI sheaths, clinical thermometer which are used in providing veterinary artificial insemination services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.